Fluorescence Imaging Detected Sarcoma Surgical Margins
Researchers explored a new imaging protocol to help surgeons better identify positive margins during cancer removal surgeries.
Updated on Oct. 12, 2026 in Cancer
A study published September 17, 2026, evaluated the use of indocyanine green fluorescence imaging to assist in identifying cancer-positive margins during surgery. The approach identified significantly more positive margins than traditional surgeon visual assessment in a group of 51 patients.
Why it matters
Incomplete removal of tumors can increase the risk of cancer returning, so surgeons often need objective tools to ensure clear margins during operations. This study examined whether fluorescence imaging could supplement surgeon intuition to improve surgical accuracy.
In an observational study of 51 patients, researchers found that indocyanine green imaging identified 14 of 15 pathology-confirmed positive margins, compared to just 4 detected by standard surgeon assessment. While the imaging was highly sensitive, its specificity was 41.7%, compared to 88.9% for surgeon intuition.
The players
University of Pittsburgh
An academic research institution where the team conducted the observational analysis of sarcoma surgical techniques.
The details
Researchers used near-infrared cameras to detect fluorescence from indocyanine green dye in tumor beds and specimens. They calculated a signal-to-background ratio to distinguish healthy tissue from cancerous margins. The study suggests that while this imaging is highly effective at highlighting potential tumor cells that the eye might miss, it is currently less precise than a surgeon's clinical judgment, leading researchers to propose combining both methods in future practice.
Timeline
Patient enrollment for the observational study occurred from April 2021 to April 2024.
Study findings were published in the Journal of Surgical Oncology on September 17, 2026.
Health Landscape
Intraoperative imaging represents an evolving frontier in cancer surgery aimed at providing surgeons with objective data during procedures. This study follows the trajectory of precision surgery, moving toward multi-modal approaches that combine technology with traditional clinical skill.
This development is primarily a clinical tool for surgeons and does not change your immediate post-operative care or treatment decisions. If you are preparing for surgery, discuss with your surgeon how they confirm tumor margins and whether they use any imaging-guided technologies.
The takeaway
While fluorescence imaging shows promise for identifying tumor margins that surgeons might miss, it is not yet a standalone solution for preventing cancer recurrence. Future randomized trials will clarify how this technology should be integrated into standard surgical workflows.
Further reading
Learn more about the latest innovations in Cancer care and surgical treatment.
Source note: This article includes information reported by Ajmc.
